Journal of Neuro Oncology: Diagnostic and therapeutic implications of IDH mutations in gliomas following the 2021 World Health Organization classification of CNS tumors.
作者信息
Juratli Tareq A, Jungk Christine, Miller Julie J
机构信息
Faculty of Medicine and University Hospital Carl Gustav Carus of Technische Universität Dresden, Department of Neurosurgery, Division of Neuro-Oncology, 01307, Dresden, Germany.
Translational Neuro-Oncology Laboratory, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA.
出版信息
J Neurooncol. 2023 May;162(3):457-459. doi: 10.1007/s11060-023-04317-3. Epub 2023 May 22.
Abstract
摘要
相似文献
1
Journal of Neuro Oncology: Diagnostic and therapeutic implications of IDH mutations in gliomas following the 2021 World Health Organization classification of CNS tumors.《神经肿瘤学杂志》：2021年世界卫生组织中枢神经系统肿瘤分类后IDH突变在胶质瘤中的诊断和治疗意义
J Neurooncol. 2023 May;162(3):457-459. doi: 10.1007/s11060-023-04317-3. Epub 2023 May 22.
2
World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.世界卫生组织 2021 年中枢神经系统肿瘤分类及其对成人型神经胶质瘤治疗的影响：综述。
JAMA Oncol. 2022 Oct 1;8(10):1493-1501. doi: 10.1001/jamaoncol.2022.2844.
3
Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system.《2021 年世界卫生组织中枢神经系统肿瘤分类的诊断、治疗和预后意义》
Cancer. 2022 Jan 1;128(1):47-58. doi: 10.1002/cncr.33918. Epub 2021 Oct 11.
4
Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities.分子神经肿瘤学的应用——弥漫性胶质瘤综合诊断及新兴分子实体综述
Diagn Pathol. 2019 Apr 9;14(1):29. doi: 10.1186/s13000-019-0802-8.
5
Diagnostic and prognostic molecular markers in common adult gliomas.常见成人脑胶质瘤的诊断和预后分子标志物。
Expert Rev Mol Diagn. 2010 Jul;10(5):637-49. doi: 10.1586/erm.10.44.
6
Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors.2021 年世界卫生组织中枢神经系统肿瘤分类发布前弥漫性神经胶质瘤的临床实验室检测实践。
Arch Pathol Lab Med. 2022 May 1;147(5):518-524. doi: 10.5858/arpa.2021-0431-CP.
7
Advances in the molecular genetics of gliomas - implications for classification and therapy.胶质母细胞瘤的分子遗传学进展——对分类和治疗的影响。
Nat Rev Clin Oncol. 2017 Jul;14(7):434-452. doi: 10.1038/nrclinonc.2016.204. Epub 2016 Dec 29.
8
Adolescents and Young Adults With Cancer: CNS Tumors.青少年和青年癌症患者：中枢神经系统肿瘤。
J Clin Oncol. 2024 Feb 20;42(6):686-695. doi: 10.1200/JCO.23.01747. Epub 2023 Dec 8.
9
[World Health Organization Classification of Central Nervous System Tumours, 5 Edition:Points of the Update and the Current Status].[《世界卫生组织中枢神经系统肿瘤分类》第5版：更新要点与现状]
No Shinkei Geka. 2023 Mar;51(2):349-363. doi: 10.11477/mf.1436204751.
10
WES data from 286 diffuse gliomas under the 2021 WHO Classification of Tumors of the Central Nervous System.286 例 2021 年版 WHO 中枢神经系统肿瘤分类弥漫性胶质瘤的 WES 数据。
Sci Data. 2022 Nov 11;9(1):692. doi: 10.1038/s41597-022-01823-3.
本文引用的文献
1
Cognitive issues in patients with IDH mutant gliomas: from neuroscience to clinical neuropsychology.IDH 突变型脑胶质瘤患者的认知问题：从神经科学到临床神经心理学。
J Neurooncol. 2023 May;162(3):525-533. doi: 10.1007/s11060-023-04289-4. Epub 2023 Mar 20.
2
Updates on the WHO diagnosis of IDH-mutant glioma.关于 IDH 突变型胶质瘤的世卫组织诊断更新。
J Neurooncol. 2023 May;162(3):461-469. doi: 10.1007/s11060-023-04250-5. Epub 2023 Jan 30.
3
Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort.老年患者的异柠檬酸脱氢酶突变型低级别胶质瘤：分子特征明确的当代队列的治疗和结局。
J Neurooncol. 2023 Feb;161(3):605-615. doi: 10.1007/s11060-022-04230-1. Epub 2023 Jan 17.
4
Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3.分析 IDH 突变型 glioma WHO 分级 2 级和 3 级采用质子放疗的安全性和疗效。
J Neurooncol. 2023 May;162(3):489-501. doi: 10.1007/s11060-022-04217-y. Epub 2023 Jan 4.
5
Proton radiotherapy in the treatment of IDH-mutant diffuse gliomas: an early experience from shanghai proton and heavy ion center.质子放疗治疗 IDH 突变型弥漫性 gliomas：上海质子重离子中心的早期经验。
J Neurooncol. 2023 May;162(3):503-514. doi: 10.1007/s11060-022-04202-5. Epub 2022 Dec 30.
6
Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.IDH 突变型 gliomas 患者中 PET 成像的临床应用和前景。
J Neurooncol. 2023 May;162(3):481-488. doi: 10.1007/s11060-022-04218-x. Epub 2022 Dec 29.
7
Conventional and emerging treatments of astrocytomas and oligodendrogliomas.星形细胞瘤和少突胶质细胞瘤的常规和新兴治疗方法。
J Neurooncol. 2023 May;162(3):471-478. doi: 10.1007/s11060-022-04216-z. Epub 2022 Dec 25.
8
DNA damage in IDH-mutant gliomas: mechanisms and clinical implications.IDH 突变型胶质瘤中的 DNA 损伤：机制与临床意义。
J Neurooncol. 2023 May;162(3):515-523. doi: 10.1007/s11060-022-04172-8. Epub 2022 Nov 9.
9
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类：概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
10
Accelerated progression of IDH mutant glioma after first recurrence.首次复发后 IDH 突变型胶质瘤的加速进展。
Neuro Oncol. 2019 May 6;21(5):669-677. doi: 10.1093/neuonc/noz016.
Zotero 插件